SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 1995
BIOPHARMACEUTICS, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 1-9370 13-3186327
(State or other (Commission File Number) (I.R.S Employer
jurisdiction of I.D. Number)
incorporation)
990 Station Road
Bellport, New York 11713
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (516) 286-5800
N/A
(Former name or former address, if changed since last report.)
1
<PAGE>
Item 5. Other Events
Press Release dated July 11, 1995 announcing SEC decision not to oppose
AMEX decision to delist stock of Biopharmaceutics, Inc.
EXHIBIT INDEX
Current Report on Form 8-K
of
Biopharmaceutics, Inc.
Date of Report: July 21, 1995
Exhibis:
28.6 Press Release dated July 11, 1995
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOPHARMACEUTICS, INC.
(Registrant)
By: /s/ Edward Fine
--------------------
Edward Fine
President, Chief Executive Officer
(Signature)
Dated: July 21, 1995
3
<PAGE>
